Covered recipient · General Payments record
GEORGE J MURAKAWA
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$49,802.92
219 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,846.00 | 8 |
| Food and Beverage | $7,884.20 | 202 |
| Consulting Fee | $5,280.00 | 2 |
| Travel and Lodging | $1,522.75 | 4 |
| Education | $269.97 | 3 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $15,988.55 | 24 |
| GENZYME CORPORATION | $15,496.42 | 25 |
| Galderma Laboratories, L.P. | $9,357.52 | 38 |
| Novartis Pharmaceuticals Corporation | $3,158.35 | 18 |
| ConvaTec Inc. | $1,713.72 | 11 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $860.57 | 19 |
| KYOWA KIRIN, INC. | $492.84 | 14 |
| Kerecis Limited | $407.39 | 9 |
| ABBVIE INC. | $403.90 | 6 |
| UCB, Inc. | $369.36 | 8 |
| LEO Pharma Inc. | $336.63 | 15 |
| Janssen Biotech, Inc. | $327.77 | 10 |
| Janssen Scientific Affairs, LLC | $156.35 | 1 |
| Arcutis Biotherapeutics, Inc. | $137.56 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $136.93 | 2 |
| Lilly USA, LLC | $131.27 | 6 |
| Regeneron Pharmaceuticals, Inc. | $123.35 | 1 |
| Biofrontera Inc. | $79.07 | 3 |
| PFIZER INC. | $73.81 | 4 |
| Surgenex LLC | $27.00 | 1 |
| Incyte Corporation | $24.56 | 1 |
Page 3 of 5; records 101–150 of 219 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GEORGE J MURAKAWA
NPI 1265422497 · CMS profile ID 102181
Allopathic & Osteopathic Physicians / Dermatology
TROY, MI
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 5; records 101–150 of 219 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1265422497?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GEORGE J MURAKAWA, NPI 1265422497, CMS profile ID 102181. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 219 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265422497?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). GEORGE J MURAKAWA, NPI 1265422497, CMS profile ID 102181. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 219 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265422497?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- GEORGE J MURAKAWA, NPI 1265422497, CMS profile ID 102181, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 219 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1265422497?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
219 matching records · $49,802.92 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 219.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $31.13 | 07/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186641221 | CMS |
| Novartis Pharmaceuticals Corporation | $1.99 | 07/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200706142 | CMS |
| GENZYME CORPORATION | $138.16 | 07/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233313596 | CMS |
| Kerecis Limited | $121.60 | 07/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1243693721 | CMS |
| ABBVIE INC. | $117.37 | 07/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203186409 | CMS |
| LEO Pharma Inc. | $20.58 | 07/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252024481 | CMS |
| Galderma Laboratories, L.P. | $16.72 | 06/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234681618 | CMS |
| Galderma Laboratories, L.P. | $3,600.00 | 06/27/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234681616 | CMS |
| Janssen Scientific Affairs, LLC | $156.35 | 06/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174174049 | CMS |
| Kerecis Limited | $8.08 | 06/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1243693727 | CMS |
| Regeneron Healthcare Solutions, Inc. | $35.68 | 06/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212995559 | CMS |
| Regeneron Healthcare Solutions, Inc. | $9,998.00 | 06/24/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212995561 | CMS |
| GENZYME CORPORATION | $139.10 | 06/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233313590 | CMS |
| GENZYME CORPORATION | $7,095.00 | 06/18/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233313592 | CMS |
| Galderma Laboratories, L.P. | $2.12 | 06/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234681614 | CMS |
| KYOWA KIRIN, INC. | $23.39 | 06/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222097593 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $29.83 | 06/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222926641 | CMS |
| Galderma Laboratories, L.P. | $137.97 | 06/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234681612 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $27.85 | 06/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250999231 | CMS |
| Janssen Biotech, Inc. | $20.55 | 06/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174876851 | CMS |
| GENZYME CORPORATION | $46.40 | 06/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233313606 | CMS |
| Galderma Laboratories, L.P. | $2.45 | 06/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234681610 | CMS |
| Regeneron Healthcare Solutions, Inc. | $143.95 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212995543 | CMS |
| Regeneron Healthcare Solutions, Inc. | $68.14 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212995545 | CMS |
| Regeneron Healthcare Solutions, Inc. | $67.58 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212995547 | CMS |
| Regeneron Healthcare Solutions, Inc. | $26.50 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212995549 | CMS |
| Regeneron Healthcare Solutions, Inc. | $59.63 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212995551 | CMS |
| Regeneron Healthcare Solutions, Inc. | $26.90 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212995553 | CMS |
| Regeneron Healthcare Solutions, Inc. | $256.33 | 06/05/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212995555 | CMS |
| Regeneron Healthcare Solutions, Inc. | $46.38 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212995557 | CMS |
| PFIZER INC. | $19.36 | 06/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231725141 | CMS |
| LEO Pharma Inc. | $3.19 | 06/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252024479 | CMS |
| Novartis Pharmaceuticals Corporation | $23.46 | 06/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200706138 | CMS |
| Novartis Pharmaceuticals Corporation | $1.92 | 06/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200706140 | CMS |
| GENZYME CORPORATION | $45.95 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233313602 | CMS |
| Galderma Laboratories, L.P. | $2.42 | 05/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234681608 | CMS |
| LEO Pharma Inc. | $21.32 | 05/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252024477 | CMS |
| Lilly USA, LLC | $22.94 | 05/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186605224 | CMS |
| Galderma Laboratories, L.P. | $18.45 | 05/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234681606 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $27.85 | 05/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250999229 | CMS |
| GENZYME CORPORATION | $9.91 | 05/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233313582 | CMS |
| Janssen Biotech, Inc. | $9.94 | 05/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174879336 | CMS |
| PFIZER INC. | $18.69 | 05/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228864580 | CMS |
| UCB, Inc. | $9.69 | 05/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224512501 | CMS |
| Regeneron Healthcare Solutions, Inc. | $35.95 | 05/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212995541 | CMS |
| ConvaTec Inc. | $49.38 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252574200 | CMS |
| KYOWA KIRIN, INC. | $23.64 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222097587 | CMS |
| Kerecis Limited | $24.55 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1243675960 | CMS |
| UCB, Inc. | $40.02 | 05/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224512499 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2,580.00 | 05/02/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212995539 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,836.51 | 10 |
| PY2025 | Principal investigator | $55,025.62 | 22 |
| PY2024 | Principal investigator | $147,486.83 | 29 |
| PY2023 | Principal investigator | $70,546.49 | 33 |
| PY2022 | Principal investigator | $106,636.77 | 51 |
| PY2021 | Recipient | $37.00 | 1 |
| PY2021 | Principal investigator | $124,203.26 | 49 |
| PY2020 | Recipient | $4,403.00 | 4 |
| PY2020 | Principal investigator | $276,077.32 | 52 |
| PY2019 | Principal investigator | $307,156.41 | 56 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
32 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $1,265.00 | 12/15/2025 | Non-covered Recipient Entity DERM CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175362146 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,265.25 | 11/25/2025 | Non-covered Recipient Entity DERM CENTER | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184264521 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $61.29 | 10/30/2025 | Non-covered Recipient Entity Somerset Skin Centre | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) | No dispute reported | 06/30/2026 | 1235993639 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,208.22 | 10/28/2025 | Non-covered Recipient Entity SOMERSET SKIN CENTER | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190304905 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,193.00 | 10/27/2025 | Non-covered Recipient Entity DERM CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175362128 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 10/20/2025 | Non-covered Recipient Entity DERM CENTER | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184251536 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,745.31 | 10/09/2025 | Non-covered Recipient Entity DERM CENTER | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184248968 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $453.78 | 10/08/2025 | Non-covered Recipient Entity SOMERSET SKIN CENTER | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190304907 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 08/22/2025 | Non-covered Recipient Entity DERM CENTER | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184229973 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,928.00 | 07/28/2025 | Non-covered Recipient Entity DERM CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175362108 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,406.00 | 07/28/2025 | Non-covered Recipient Entity DERM CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175362115 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,345.00 | 06/30/2025 | Non-covered Recipient Entity DERM CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175362101 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $53.20 | 06/27/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184120809 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $64.00 | 06/27/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184120811 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $51.86 | 06/12/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184120795 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $57.46 | 06/12/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184120797 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $98.90 | 06/12/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184120799 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $103.02 | 06/12/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184120801 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $127.07 | 06/12/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184120803 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $351.03 | 06/12/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184120805 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $418.88 | 06/12/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184120807 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,477.00 | 05/26/2025 | Non-covered Recipient Entity DERM CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175362075 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $511.09 | 04/29/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184120793 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,345.00 | 04/28/2025 | Non-covered Recipient Entity DERM CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175362136 |
| Principal investigator 1 | Amgen Inc. | $4,131.00 | 04/24/2025 | Non-covered Recipient Entity DERM CENTER | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246640695 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,087.00 | 03/24/2025 | Non-covered Recipient Entity DERM CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175362122 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,200.00 | 03/17/2025 | Non-covered Recipient Entity Derm Center | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226082438 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,954.00 | 03/03/2025 | Non-covered Recipient Entity DERM CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175362093 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 02/20/2025 | Non-covered Recipient Entity DERM CENTER | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155106 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 02/20/2025 | Non-covered Recipient Entity DERM CENTER | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155108 |
| Principal investigator 1 | Amgen Inc. | $6,483.77 | 01/27/2025 | Non-covered Recipient Entity SOMERSET SKIN CENTRE | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246648313 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,882.00 | 01/27/2025 | Non-covered Recipient Entity DERM CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175362083 |